Aggiornato
Signs Memorandum of Understanding with Attwill
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year
Through Large Scale Lyophilization, Tableting and Coating
establish AMS as a resource for lyophilization development and large scale manufacturing including tableting and enteric coating for Vaxart’s oral COVID-19 vaccine.
AMS will be assigning dedicated resources and equipment for the scale up and commercial production of the vaccine upon entering a formal agreement.
investors.vaxart.com/news-releases/news-release-details/vaxart-inc-signs-memorandum-understanding-attwill-medical
Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year
Through Large Scale Lyophilization, Tableting and Coating
establish AMS as a resource for lyophilization development and large scale manufacturing including tableting and enteric coating for Vaxart’s oral COVID-19 vaccine.
AMS will be assigning dedicated resources and equipment for the scale up and commercial production of the vaccine upon entering a formal agreement.
investors.vaxart.com/news-releases/news-release-details/vaxart-inc-signs-memorandum-understanding-attwill-medical
Trade attivo
Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speedtoday announced that its oral COVID-19 vaccine has been selected to participate in a non-human primate (NHP) challenge study, organized and funded by Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021.
The study is designed to demonstrate the efficacy of Vaxart’s oral COVID-19 vaccine candidate.
finance.yahoo.com/news/vaxart-covid-19-vaccine-selected-120010175.html
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.